Proteins for life
ExpreS2ion develops a portfolio of vaccines for diseases such as COVID-19, influenza and breast cancer through the use of its non-viral Drosophila S2 cells-based expression system, ExpreS2, that is recognized for handling even the toughest protein challenges.
The company also collaborates on additional projects, including several malaria vaccines, and offers a range of protein expression and production services from discovery to pre-clinical development and cGMP production.
Latest press release
Scientific article about the advantageous S2-based protein secretion system ExpreS2 and a moderate-throughput research variant called FAS2FURIOUS
Hørsholm, Denmark, May 9, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that Frontiers in Bioengineering and Biotechnology published an article about the ability of S2 cells to express challenging targets.Read more